Petredis Investment Advisors LLC Purchases 122 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Petredis Investment Advisors LLC boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 11,716 shares of the medical equipment provider’s stock after purchasing an additional 122 shares during the quarter. Petredis Investment Advisors LLC’s holdings in Intuitive Surgical were worth $5,803,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Atala Financial Inc bought a new stake in shares of Intuitive Surgical during the fourth quarter valued at approximately $25,000. Parvin Asset Management LLC purchased a new stake in Intuitive Surgical during the 4th quarter valued at $26,000. Global Financial Private Client LLC boosted its stake in Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 38 shares during the last quarter. BankPlus Trust Department bought a new stake in shares of Intuitive Surgical in the 4th quarter worth $28,000. Finally, Hurley Capital LLC purchased a new position in shares of Intuitive Surgical in the fourth quarter worth $28,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG opened at $526.15 on Tuesday. The stock has a market cap of $188.58 billion, a price-to-earnings ratio of 82.08, a price-to-earnings-growth ratio of 5.85 and a beta of 1.67. The firm’s fifty day moving average is $522.38 and its 200 day moving average is $539.01. Intuitive Surgical, Inc. has a fifty-two week low of $413.52 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. The business had revenue of $2.25 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the firm posted $1.50 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the firm’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president now directly owns 907 shares of the company’s stock, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the business’s stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the transaction, the director now directly owns 6,371 shares in the company, valued at approximately $3,312,920. This represents a 27.36% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,543 shares of company stock valued at $8,375,072. Corporate insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ISRG shares. Piper Sandler lowered their price target on Intuitive Surgical from $670.00 to $575.00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. Barclays lowered their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. Robert W. Baird dropped their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an “outperform” rating on the stock in a report on Wednesday, April 23rd. Truist Financial decreased their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. Finally, Citigroup restated a “buy” rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $588.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.